0.82 USD
↗ 0.01 (0.75%)AT CLOSE (11:59 AM EDT)
Genprex, Inc. Common Stock
GNPXNASDAQ • USD
0.84
↗ 0.01 (1.69%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
0.84
↗ 0.01 (1.69%)
Market: CLOSED
Open?$0.82
High?$0.86
Low?$0.82
Prev. Close?$0.82
Volume?238.7K
Avg. Volume?937.3K
VWAP?$0.84
Rel. Volume?0.25x
Bid / Ask
Bid?$0.82 × 3.0K
Ask?$0.85 × 500
Spread?$0.02
Midpoint?$0.84
Valuation & Ratios
Market Cap?8.7M
Shares Out?10.6M
Float?40.4M
Float %?94.2%
P/E Ratio?N/A
P/B Ratio?0.51
EPS?-$1.58
Dividend?0.00%
Ex-Dividend?N/A
GNPX is currently priced at $0.82. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest GNPX is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of May 22, 2026.
News
Profile
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Themes
Address
1601 TRINITY STREET, BLDG. B
AUSTIN, TX 78712
Phone: 512-537-7997
AUSTIN, TX 78712
Phone: 512-537-7997
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?80
Piotroski F-Score?0/9Weak
Altman Z-Score?-12.25Distress
Confidence?40%Low
Short InterestLow
Short % of Float?2.78%Low
Short Interest?1.1M
Days to Cover?1.0
Free Float40.4M
Avg Daily Volume2.0M
Settlement Date2026-04-30
Financial Health
Current Ratio?5.61Strong
Quick Ratio?5.61Strong
Cash Ratio?5.38Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.51CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?0.6CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-98.8%WEAK▾
S&P3
ROA?-82.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$-9368405
Fundamentals ratios updated end of day